3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
Radiosurgery
5
Androgen Antagonists
4
enzalutamide
2
Prednisone
2
Docetaxel
2
talazoparib
1
sipuleucel-T
1
rucaparib
1
olaparib
1
gallium 68 PSMA-11
1
darolutamide
1
cabazitaxel
1
apalutamide
1
XRP6258
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hematologic Tests
1
Granulocyte Colony-Stimulating Factor
1
Gonadotropin-Releasing Hormone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostate Cancer Metastatic
×
olaparib
×
Clear all
NCT03434158
2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
16 enrolled